CA2684977C - A method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant - Google Patents

A method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant Download PDF

Info

Publication number
CA2684977C
CA2684977C CA2684977A CA2684977A CA2684977C CA 2684977 C CA2684977 C CA 2684977C CA 2684977 A CA2684977 A CA 2684977A CA 2684977 A CA2684977 A CA 2684977A CA 2684977 C CA2684977 C CA 2684977C
Authority
CA
Canada
Prior art keywords
pharmaceutically compatible
water
rasagiline
soluble
adjuvant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2684977A
Other languages
French (fr)
Other versions
CA2684977A1 (en
Inventor
Alexander Lehmann
Frank Muskulus
Julia Schulze Nahrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Publication of CA2684977A1 publication Critical patent/CA2684977A1/en
Application granted granted Critical
Publication of CA2684977C publication Critical patent/CA2684977C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to an adsorbate of a pharmaceutically compatible rasagiline salt comprising at least one pharmaceutically compatible adjuvant, wherein the at least one pharmaceutically compatible adjuvant is a water-soluble, organic solvent and the rasagiline salt is present in the adsorbate as an amorphous substance.

Description

A Method for the Production of Adsorbates of a Rasagiline Salt Having a water-soluble Adjuvant The present invention relates to novel adsorbates of pharmaceutically compatible salts of the known active ingredient rasagiline with water-soluble, pharmaceutically compatible, or-ganic adjuvants and methods for the production thereof. In these novel adsorbates, the pharmaceutically compatible salt of the rasagiline is present in an amorphous form which is stable and does not convert to a different, for example crystalline, form of the pharmaceuti-cally compatible salt of rasagiline even upon lengthy storage after incorporation of the ad-sorbate into a pharmaceutical product.
Rasagiline is the designation for the chemical compound R(+)-N-propargy1-1-aminoindane which is also called R(+)PAI.
Rasagiline is an MAO inhibitor known for a long time which is used as an active ingredient in the treatment of a number of diseases, For example, US-A 5,532,415 discloses the preparation of rasagiline and its salts as well as the application of the active ingredient in the treatment of a number of diseases, e.g. Parkinson's disease, memory disorders, demen-tia, depression, schizophrenia, hyperactivity, etc. A method for preparing salts of rasagiline is also disclosed in WO 02/068376.
Even though rasagiline and its salts have been described as pharmaceutical active ingredi-ents for quite some time, the formulation of pharmaceutical products with pharmaceutically compatible salts of rasagiline poses problems. For example, US-A 6,126,968 describes that pharmaceutical formulations with PAI which may be present either as a racemate or as a (+)- or (-)-enantiomer suffer from stability problems. To solve these problems, US-A
6,126,968 proposes to formulate the active ingredients with a very large quantity of an or-ganic alcohol such as, especially, mannitol. WO 2006/091657 reports problems resulting from the fact that the homogeneous distribution of a rasagiline salt in a pharmaceutical product required by the law on pharmaceutical products cannot be fully guaranteed. In order to solve this problem, WO 2006/091657 proposes to use active ingredient particles of a cer-tain size.
It is also becoming increasingly important in the field of the formulation of pharmaceutical products that the physical form of an active ingredient (i.e. the polymorphous or amorphous form) does not change during storage of the pharmaceutical formulation and that the phar-maceutical products contain the active ingredient in a defined and reproducible polymor-phous or amorphous form. The pharmaceutically compatible rasagiline salts are commonly present in the crystalline form; therefore, the occurrence of polymorphous substances is highly likely. If such polymorphous forms are incorporated into pharmaceutical products, it is advantageous to use a pure polymorphous form, and it must be ensured that no conver-sion between the individual polymorphous substances in the pharmaceutical product oc-curs. Therefore, it would be advantageous to provide rasagiline in an amorphous form which may be reproduced easily, is amenable to processing and does not convert to other forms. However, it has not been possible so far to reproducibly provide the pharmaceutically compatible salts of rasagiline in a stable amorphous form which is suitable for formulating pharmaceutical products.
Therefore, it is the object of the invention to provide pharmaceutically compatible salts of rasagiline in such a form that, after incorporation into a pharmaceutical product, the active ingredient will remain stable throughout the storage period of the pharmaceutical product, that no conversions to other physical forms of the active ingredient occur and that homoge-neity of the distribution of the active ingredient in the pharmaceutical products can be en-sured in a simple manner. In addition, the preparation and processing of the form of the pharmaceutically compatible salts of rasagiline should be easy.
This object is achieved by the surprising finding that, after removal of the solvent, aqueous solutions comprising a pharmaceutically compatible salt of rasagiline and a water-soluble, organic, pharmaceutically compatible adjuvant form adsorbates between the pharmaceuti-cally compatible salt of rasagiline and the pharmaceutically compatible organic adjuvant where the pharmaceutically compatible salt of rasagiline is present in an amorphous form.
These adsorbates may be processed easily, are highly stable in pharmaceutical formula-tions, especially in tablets, capsules, pellets and granulate, and they provide pharmaceutical products with high homogeneity in the distribution of the active ingredient.
In particular, the amorphous form of the rasagiline salts does not convert to other physical forms after incor-poration into pharmaceutical products and during the storage thereof.
Therefore, the invention provides an adsorbate of a pharmaceutically compatible salt of rasagiline comprising at least one pharmaceutically compatible adjuvant, said at least one pharmaceutically compatible adjuvant being a water-soluble, organic adjuvant and the salt of rasagiline being present as an amorphous substance in the adsorbate. These adsorbates may be obtained by a process wherein a pharmaceutically compatible salt of rasagiline and at least one pharmaceutically compatible, water-soluble, organic adjuvant are dissolved in an aqueous medium and the aqueous medium is then removed. The invention also pro-vides a process for preparing the adsorbates and pharmaceutical products containing these adsorbates. The following observations apply both to the adsorbates of the invention and to the process for the preparation thereof.
The invention also provides a process for the production of adsorbate comprising an amor-phous form of a pharmaceutically compatible salt of rasagiline and at least one pharmaceu-tically compatible, water-soluble, organic adjuvant, wherein the process comprises:
(a) dissolving the pharmaceutically compatible salt of rasagiline and the at least one pharmaceutically compatible, water-soluble organic adjuvant in an aqueous me-dium to form a solution, and (b) spray drying the solution to remove the aqueous medium, thereby forming the adsorbate.
The adsorbates of the invention preferably do not contain an inorganic adjuvant.
During preparation, pharmaceutically compatible salts of rasagiline are generally present as a crystalline substance. When these salts are dissolved in water (or an aqueous solvent) and the water is then removed (for example by spray drying), crystalline or partially crystal-line substances are obtained in turn. It has now been surprisingly found that, in the event that a pharmaceutically compatible rasagiline salt is dissolved with an organic, water-soluble, pharmaceutically compatible adjuvant and the water is then removed, for example by spray drying, an adsorbate between the pharmaceutically compatible rasagiline salt and the organic, water-soluble, pharmaceutically compatible adjuvant is obtained wherein the pharmaceutically compatible rasagiline salt is present in an amorphous form.

3a In this invention, an amorphous form is interpreted to mean a form of the active ingredient wherein the diffraction reflexes of the active ingredient no longer show in an X-ray diffracto-gram. For details regarding the determination of the X-ray diffractogram, reference is made to the following examples.
The pharmaceutically compatible rasagiline salts are not subject to special limitations; any of the customary pharmaceutically compatible salts may be used for this purpose. Preferred salts are the tartrates, the esylates, the mesylates, the edisilates and the sulfates. The me-sylate salt of rasagiline is most preferred.
In a preferred embodiment of the invention, the adsorbate consists of the pharmaceutically compatible rasagiline salt and one or more, preferably one, pharmaceutically compatible, water-soluble, organic adjuvant. In this embodiment, the adsorbate does not contain any water-insoluble components and no inorganic components.
In another preferred embodiment, the adsorbate consists of the pharmaceutically compati-ble rasagiline salt and one or more, preferably one, pharmaceutically compatible, organic, water-soluble adjuvant and one or more, preferably one, water-insoluble adjuvant. Prefera-bly, the water-insoluble adjuvant is also an organic compound; the presence or inorganic compounds in the adsorbates is not preferred for the invention.
If water-insoluble, pharmaceutically compatible adjuvants are components of the adsorbate, these are preferably water-insoluble, pharmaceutically compatible adjuvants having a parti-cle size of 150 pm or less, preferably 100 pm or less, especially preferably in the range of approx. 50 pm. The lower limit of the particle size of the pharmaceutically compatible, wa-ter-insoluble adjuvants is about 10 pm, more preferably about 20 pm.
Preferably, this adju-vant is microcrystalline cellulose, especially preferably microcrystalline cellulose having a mean particle size of 150 pm or less, more preferably 100 pm or less, especially about 50 pm. Especially preferably, said microcrystalline cellulose is Avicel PH101.
An essential component of the adsorbates of the invention is at least one pharmaceutically compatible adjuvant which is a water-soluble organic adjuvant. The adsorbate of the inven-tion preferably contains a water-soluble, organic, pharmaceutically compatible adjuvant, but it is also possible to use several water-soluble, pharmaceutically compatible, organic adju-vants, for example two, three or four such adjuvants.
The pharmaceutically compatible, water-soluble, organic adjuvants are preferably water-soluble polymers such as those used as binders for pharmaceutical products in the prior art, e.g. cellulose ether or polyvinyl pyrrolidone. Especially preferred are hydroxypropyl methyl cellulose, hydroxypropyl cellulose or polyvinyl pyrrolidone. If such a water-soluble polymer is used as the water-soluble, organic, pharmaceutically compatible adjuvant, the adsorbate preferably does not comprise any water-insoluble adjuvant.

Another preferred water-soluble adjuvant is an organic acid such as an organic mono-, di-or tricarboxylic acid having up to 10 carbon atoms which, optionally and preferably, contains one to three hydroxyl groups. The most preferred organic, water-soluble acid is citric acid. If the organic, pharmaceutical, water-soluble adjuvant is not a water-soluble polymer, but, for example, an organic, water-soluble acid such as citric acid, it is preferred to use this or-ganic, water-soluble, pharmaceutically compatible adjuvant together with a water-insoluble, pharmaceutically compatible adjuvant as defined above. It goes without saying that any salt of this acid may be used instead of the organic acid.
The ratio between the pharmaceutically compatible rasagiline salt and the at least one pharmaceutically compatible, water-soluble, organic adjuvant in the adsorbate is preferably in the range of 5 : 1 to 1 : 20, more preferably in the range of 2 : 1 to 1 :
15. It is most pre-ferred that the amount of the pharmaceutically compatible, water-soluble, organic adjuvant is at least as high as or higher than the amount of the pharmaceutically compatible rasagiline salt so that the ratio between the salt and the adjuvant is most preferably in the range of 1 : 1 to 1 : 10.
If more than one pharmaceutically compatible, water-soluble, organic adjuvant is present in the adsorbate, the above statements regarding the ratio between the pharmaceutically compatible rasagiline salt and the at least one pharmaceutically compatible, water-soluble organic adjuvant also apply for the preferred ratios between the pharmaceutically compati-ble rasagiline salt and the total of all the pharmaceutically compatible, water-soluble, or-ganic adjuvants in the adsorbate. If one or more water-insoluble, pharmaceutically compati-ble adjuvants are present in the adsorbate of the invention, the ratio between the pharma-ceutically compatible rasagiline salt and the one or more (preferably one) pharmaceutically compatible, water-insoluble adjuvants is preferably in the range of 5: 1 to 1 : 20, more pref-erably in the range of 2 : 1 to 1 : 15, and most preferably in the range of 1 : 1 to 1 : 10.
Unless expressly disclosed otherwise or evident to a person skilled in the art from the cir-cumstances, any ratios, percentages and contents specified in this application are based on the weight.
An adjuvant within the meaning of the present application is water-soluble if more than 0.1 mg of the adjuvant may be dissolved in 1 ml of water. Preferably, a water-soluble adjuvant =
, is soluble to such an extent that more than 1 mg, more preferably more than 10 mg, espe-cially more than 100 mg, e.g. 1000 mg or more may be dissolved in 1 ml of water.
An adjuvant within the meaning of the present application is water-insoluble if not more than 0.1 mg of the active ingredient may be dissolved in 1 ml of water.
In each case, the solubilities are based on distilled water at 25 C and pH =
7.
The adsorbates of the invention may be prepared in a simple manner by dissolving a phar-maceutically compatible rasagiline salt and the at least one organic, water-soluble, pharma-ceutically compatible adjuvant as well as, optionally, other water-soluble components of the adsorbate in water or an aqueous solvent. If water-insoluble components should be present in the adsorbate, these water-insoluble components are dispersed in the solvent subse-quently (or in advance). Then the solvent is removed, preferably by spray drying. Such spray drying may be conducted in the customary manner, for example with a BUchi spray dryer of the type B-191, for example at a temperature of 130 C and a spray rate of 5, 10 or 20 %. However, the spray drying conditions are not critical as long as no temperature is used at which the rasagiline decomposes during the spraying period.
In the invention, an aqueous solvent is interpreted to mean a solvent at least 50 %, more preferably 70 %, of which consist of water, the remainder consisting of one or more water-miscible solvents, especially of an alcohol such as ethanol or isopropanol. It is preferred to use water as the solvent in the method of the invention to prepare the adsorbates of the invention.
The adsorbates of the invention may be processed in the customary manner to obtain pharmaceutical products. If desired, the adsorbates may be ground to an advantageous particle size and screened to an advantageous particle distribution.
The adsorbates of the invention may generally be designed for oral, parenteral, rectal or transdermal administration, preferably oral administration. Suitable forms of administration, for example, are tablets (prepared by granulation or direct compression), tablets disintegrat-ing in the mouth, delayed-release tablets, pellets or granulates that may, for example, be introduced into coated tablets, sachets, hard or soft gelatine capsules, etc.
Processing to obtain tablets, pellets or granules is carried out as described in the prior art and known to a =

person skilled in the art. For example, reference may be made to the standard textbook "Die Tablette", Wolfgang A. Ritschel and Anette Bauer-Brandl, 2nd ed., Editio Cantor Verlag, 2002.
The tablets, pellets or granules of the invention, may, for example, comprise suitable carrier substances (e.g. fillers), binders, lubricants, disintegrants, dyes, flavouring agents, fluidis-ers, film-coats and, optionally, fluxing agents and other customary adjuvants and additives.
Suitable carriers, for example, are pellets on a sugar basis and microcrystalline basis, lac-tose, a-lactose monohydrate, gelatine, agar, starch, corn starch, sucrose, glucose, methyl cellulose, dicalcium phosphate, calcium phosphate, calcium silicates, mannitol, sorbitol, microcrystalline cellulose, cellulose derivatives, fatty acid, fats, stearates, oils, waxes, paraf-fins, etc. Suitable binders comprise starch, gelatine, natural sugars such as glucose or 11-lactose, starch, gum Arabic, tragacanth, sodium alginate, povidone, carboxymethyl cellu-lose, polyethylene glycol, wax, hydroxypropyl methyl cellulose, hydroxypropyl cellulose etc.
Examples of lubricants are sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, stearic acid, sodium stearyl fumarate, talcum powder, etc. Disintegrants include the well-known "super disintegrants", but starch, methyl cellulose, agar, bentonite, xanthan gum, pyrrolidones, etc. are also worth mentioning. Espe-cially preferred are sodium crosscarmelose und sodium starch glycolate.
Suitable film coats and functional enteric and retarding film coats are celluloses and derivatives thereof, poly-glycols, povidones, acryl polymers, copolymers on the basis of ethyl acrylate, methyl methacrylate, polyvinyl acetate and methacrylic acid. In addition, the pharmaceutical prod-ucts may, for example, comprise suitable dyes on the basis of iron oxide.
It was already known to formulate pharmaceutically compatible rasagiline salts with the above adjuvants. These adjuvants also include pharmaceutically compatible, water-soluble, organic compounds. However, the adsorbates of the invention are not the result of process-ing these pharmaceutically compatible, water-soluble, organic compounds with a pharma-ceutically compatible rasagiline salt and are therefore novel compounds. In order to obtain such adsorbates it is not sufficient to process the pharmaceutically compatible rasagiline salts with adjuvants in the usual manner to obtain pharmaceutical products.
Rather, a solu-tion of the pharmaceutically compatible rasagiline salt and the pharmaceutically compatible, water-soluble, organic adjuvants that are to yield the adsorbate must be formed and the water then removed to yield the adsorbate. The adsorbates prepared in this manner are novel and have not been described before in the prior art.

The following examples will illustrate the invention.
In the examples, the degree of amorphism was tested by X-ray diffractometry.
These measurements are carried out on a Bruker Advance D8, with a Theta-2Theta goniometer (435 mm diameter) in reflexion geometry (Bragg-Brentano). The radiation power of the X-ray tube (copper anode Kat A = 1,5406 A / Ka2, A = 1,54439 A) is selected at a generator output of 40 KV/40 mA, and a divergence aperture of 0.6 mm. As a position sensitive detec-tor PSD, a Vantec-1 Detector (12 20 detector aperture angle) is used. X-ray diffractions are taken in the range from 3 20 to 550 20, at a step distance of 0,016 20 (steps 2465) step time: 75 ns. A secondary nickel filter (0.1 mm) is used to filter the Cu-K13 radiation (A =
1,39222 A). Primary and secondary SoIler gap (2.5 ), anti-scattering aperture 5.59 (fixed, distance to the detector window = 110.8 mm). Detector aperture (static) 10.28 mm, distance to the detector window = 21.3 mm).
The samples are introduced by a horizontal sample changer (9 samples). In order to verify that the measuring array operates correctly, a Korund standard sample is measured before each series of measurements. The intensities (a1/a2 = 0.5) and reflex positions as well as the al-a2 reflex distances of this measurement are superimposed with a reference diffrac-tion diagram. This evaluation and the evaluation of the results of the sample measurements as well as the further processing of the raw data is made with the programme package EVA
(Bruker).
Rasagiline mesylate prepared in accordance with US-A-5,532,415 was used for the follow-ing experiments.
Reference example 1 2 g of rasagiline mesylate were dissolved in 50 g of water in a beaker and spray dried with a Buchi type B-191 spray dryer. The following were selected: spray drying temperature 130 C, spray rate 10 %, aspirator power 75 % and flow control (spray pressure) 50 %. The product thus obtained was then examined by X-ray diffraction. Fig. 1 shows the diffracto-gram.

The usual X-ray diffraction peaks of a crystalline rasagiline mesylate are visible. For com-parison, a typical rasagiline mesylate X-ray diffractogram is shown in Fig. 7.
Example 1 Adsorbates of rasagiline with different adjuvants were prepared in accordance with the fol-lowing table:
Example a Rasagiline mesylate 1 g 1 g 1 g 1 g 1 g 1 g Kollidon 25 1 g 9 g HPMC 1 g 9g Citric acid 1 g 9 g Avicel PH101 1 g 9 g X-ray diffractogram Fig. 2 Fig. 3 Fig. 4 Fig. 5 Fig. 6 In each of the experiments according to example la, 1 b, id, and le the amount of rasagiline mesylate indicated in the above table and the indicated amount of water-soluble adjuvant were dissolved in 50 g of water in a beaker and spray dried with the Bijchi type B-191 spray drier. The selected spray drying temperature was 130 C, the spray rate 10 %, the aspirator power 75 %, and the flow control (spray pressure) 50 %.
The indicated amount of Avicel PH 101 was used additionally in the experiments 1 c and if.
In that case, the experiment was carried out as follows: The amount of rasagiline mesylate indicated in the above Table and the indicated amount of water-soluble adjuvant are dis-solved in 50 g of water in a beaker. Then the water-insoluble adjuvant Avicel PH 101 as described in the above Table was added and mixed in. Following that, the aqueous solu-tions or mixtures, respectively, were spray dried with the Bijchi B-191 spray dryer. The spray drying temperature selected was 130 C, the spray rate 10 %, the aspirator power 75 % and the flow control (spray pressure) 50 %.
Kollidon 25 is a water-soluble polyvinyl pyrrolidone. Hypromellose (HPMC) was selected as the cellulose derivative. The commercial trade name of the citric acid used is "Zitronen-saure, wasserfrei, Granulat" (anhydrous, granulate).

=
X-ray diffraction diagrams as shown in the Figures were taken of the adsorbates.
It was possible to show that the mesylate salt of rasagiline is present in amorphised form in the adsorbates; there is no trace of the typical X-ray diffraction peaks.
Example la (Fig. 2) was fixed to a substrate with glue and tested, because there was not enough amorphous substance. The peaks evident here are caused by the substrate. This was confirmed by the examination of crystalline rasagiline mesylate applied to the same substrate (Fig. 8).
Example 2 Example 2 describes a selected process of preparing a solid dosage form comprising a rasagiline mesylate adsorbate of example 1d.
Composition:
No. Substance Function [mg]
Rasagiline mesylate 1 API 3.27 adsorbate 2 Avicel PH 101 Filler 184.80 3 Starch 1500 Disintegrant 10.00 4 Aerosil R972 Flow control agent 1.20 5 Mg Stearate Lubricant 2.00 6 Total 201.27 Method of preparation:
Weigh in rasagiline mesylate adsorbate, Avicel PH 101 and Starch 1500 and mix for 5 min-utes in a Turbula at 23 rpm. Then screen the mixture through a hand sieve of 0.5 mm and mix for 5 minutes. Add Aerosil R972 and mix in the Turbula for 5 minutes.
Screen the mix-ture through a hand sieve 0.5 mm and mix for 5 minutes. Add magnesium stearate and mix in the Turbula for 5 minutes. Compress to 8 mm cores with EKO.

, Example 3 Example 2 was repeated with the difference that the adsorbate of example la was used instead of the adsorbate of example id. The 3.27 mg of rasagiline adsorbate correspond to 1 mg of rasagiline base.
Example 4 Rasagiline tablets according to example 3 were stored in open or sealed glass bottles, re-spectively, for up to 12 weeks at 40 C and 75 % relative humidity (RH). At certain points in time, samples were taken and the appearance, hardness, disintegration time and water content (Kart-Fischer titration) of the tablets determined. In addition, the content of the ac-tive ingredient and its optical purity as well as the content of related substances was deter-mined by HPLC. In addition, it was investigated by X-ray diffractometry (XRPD) whether the amorphous active ingredient converted to different physical forms. The active ingredient turned out to be sufficiently stable, especially with a view to its physical form. Fig. 9 shows X-ray diffractograms of samples at the beginning of the experiment (5) and after 4 (4) and 12 (2) weeks of storage at 40 C, 75 % RH in a sealed container and after 4 (3) and 12 (1) weeks of storage at 40 C, 75 % RH in a open container as well as of crystalline rasagiline mesylate (6). It turned out that no crystallisation of the rasagiline salt occurs even after stor-age.

Claims (13)

Claims
1. A process for the production of adsorbate comprising an amorphous form of a pharmaceutically compatible salt of rasagiline and at least one pharmaceutically compatible, water-soluble, organic adjuvant, wherein the process comprises:
(a) dissolving the pharmaceutically compatible salt of rasagiline and the at least one pharmaceutically compatible, water-soluble organic adjuvant in an aqueous medium to form a solution, and (b) spray drying the solution to remove the aqueous medium, thereby forming the adsorbate.
2. The process according to claim 1, in which the pharmaceutically compatible salt of rasagiline is the mesylate salt.
3. The process according to claim 1 or 2, in which the adsorbate consists of the pharmaceutically compatible salt of rasagiline and the at least one pharmaceutically compatible, water-soluble, organic adjuvant.
4. The process according to claim 1 or 2, in which step (a) further comprises adding one or more pharmaceutically compatible, water-insoluble adjuvant(s) to the solution while mixing.
5. The process according to claim 4, in which the pharmaceutically compatible, water-insoluble adjuvant is microcrystalline cellulose.
6. The process according to any one of claims 1 to 5, in which the at least one water-soluble, organic, pharmaceutically compatible adjuvant is a water-soluble, pharmaceutically compatible cellulose ether; a water-soluble polyvinyl pyrrolidone;
a water-soluble, pharmaceutically compatible organic acid; or any combination thereof.
7. The process according to claim 6, in which the at least one water-soluble, organic, pharmaceutically compatible adjuvant is hydroxypropyl methyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone or citric acid.
8. The process according to any one of claims 1 to 7, in which the weight ratio between the pharmaceutically compatible salt of rasagiline and the total weight of the at least one pharmaceutically compatible, water-soluble, organic adjuvant is in the range from 5 : 1 to 1 : 20.
9. The process according to claim 8, in which the weight ratio between the pharmaceutically compatible salt of rasagiline and the at least one pharmaceutically compatible water-soluble, organic adjuvant is in the range from 1 : 1 to 1 : 10.
10. An adsorbate, obtained by the process of any one of claims 1 to 9.
11. A drug containing the adsorbate of claim 10 and one or more pharmaceutically compatible adjuvant(s) or additive substance(s).
12. The drug according to claim 11 that is a capsule, tablet, a tablet disintegrating in the mouth, a delayed-release tablet, pellets or a granulate.
13. The drug according to claim 11 or 12, which comprises 1.0 mg of the pharmaceutically compatible salt of rasagiline.
CA2684977A 2007-04-30 2008-04-30 A method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant Expired - Fee Related CA2684977C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07008755A EP1987816A1 (en) 2007-04-30 2007-04-30 Adsorbate of a rasagiline salt with a water-soluble inactive ingredient
EP07008755.6 2007-04-30
PCT/EP2008/003498 WO2008131961A1 (en) 2007-04-30 2008-04-30 Method for the production of adsorbates of a rasagiline salt having a water soluble adjuvant

Publications (2)

Publication Number Publication Date
CA2684977A1 CA2684977A1 (en) 2008-11-06
CA2684977C true CA2684977C (en) 2015-02-24

Family

ID=38190820

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2684977A Expired - Fee Related CA2684977C (en) 2007-04-30 2008-04-30 A method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant

Country Status (4)

Country Link
US (2) US20100137447A1 (en)
EP (2) EP1987816A1 (en)
CA (1) CA2684977C (en)
WO (1) WO2008131961A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
CN101098685A (en) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 Rasagiline orally disintegrating compositions
JP5738509B2 (en) 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド Rasagiline formulation with improved content uniformity
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1991214B1 (en) * 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CN101442997B (en) * 2006-04-03 2012-11-14 泰华制药工业有限公司 Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (en) 2006-08-18 2008-02-27 Ratiopharm GmbH New salts of the active component rasagiline
NZ577623A (en) 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
AU2007334428B2 (en) 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
EP2194780A4 (en) * 2007-09-05 2010-10-27 Teva Pharma Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CN101909438A (en) * 2008-01-11 2010-12-08 泰华制药工业有限公司 Rasagiline formulations, their preparation and use
WO2009118657A2 (en) * 2008-03-28 2009-10-01 Medichem, S.A. Polymorphic form of an aminoindan mesylate derivative
WO2009147430A1 (en) 2008-06-02 2009-12-10 Generics [Uk] Limited A process for the preparation of enantiomerically pure amines
EP2285214B1 (en) * 2008-06-10 2012-05-16 Teva Pharmaceutical Industries Ltd. Rasagiline soft gelatin capsules
MX2010013766A (en) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagiline for parkinson's disease modification.
WO2009154782A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
AU2009260728B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
EP2321258A1 (en) * 2008-07-30 2011-05-18 Generics [UK] Limited Polymorphic form of rasagiline mesylate
DE102008064061A1 (en) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Solid composition with the active ingredient rasagiline
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
EP2451771B1 (en) 2009-07-09 2014-06-18 Ratiopharm GmbH Salts of rasagiline and pharmaceutical preparations thereof
WO2011121607A2 (en) 2010-03-29 2011-10-06 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
JP2013533287A (en) 2010-07-27 2013-08-22 テバ ファーマシューティカル インダストリーズ リミティド Use of rasagiline for the treatment of olfactory dysfunction
JP2013537530A (en) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド Rasagiline citrate dispersion
EP2705021A2 (en) 2011-05-04 2014-03-12 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
KR20140090996A (en) 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-formyl-propargyl-aminoindan
EP2766004A4 (en) 2011-10-10 2015-04-22 Teva Pharma R(+)-n-methyl-propargyl-aminoindan
DE102012000786A1 (en) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Process for the preparation of a solid pharmaceutical composition containing the active substance rasagiline
WO2013175493A1 (en) * 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
AR092168A1 (en) 2012-08-17 2015-03-25 Teva Pharma PARENTERAL FORMULATIONS OF RASAGILINA
IN2013MU01782A (en) * 2013-05-20 2015-06-26 Cadila Healthcare Ltd
EP3079672B1 (en) * 2013-12-11 2020-05-13 KRKA, d.d., Novo mesto Pharmaceutical composition comprising a pharmaceutically acceptable salt of rasagiline

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL130528A (en) * 1996-12-18 2004-12-15 Teva Pharma Aminoindan derivatives, pharmaceutical compositions comprising them and uses thereof
US6630614B1 (en) * 2000-02-29 2003-10-07 Pioneer Hi-Bred International, Inc. Rad21 orthologue and uses thereof
EA006777B1 (en) * 2001-06-22 2006-04-28 Пфайзер Продактс Инк. Pharmaceutical compositions of adsorbates of amorphous drug
EP2526944B1 (en) * 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
KR20070036797A (en) * 2004-07-26 2007-04-03 테바 파마슈티컬 인더스트리즈 리미티드 Dosage forms with an enterically coated core tablet
AU2005309817B2 (en) * 2004-11-24 2011-08-18 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
CN101098685A (en) * 2004-11-24 2008-01-02 特瓦制药工业有限公司 Rasagiline orally disintegrating compositions
WO2006058250A2 (en) * 2004-11-24 2006-06-01 Spi Pharma, Inc. Orally disintegrating compositions
ES2420404T3 (en) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
JP5738509B2 (en) * 2005-02-23 2015-06-24 テバ ファーマシューティカル インダストリーズ リミティド Rasagiline formulation with improved content uniformity
US7671630B2 (en) * 2005-07-29 2010-03-02 Synopsys, Inc. USB 2.0 HS voltage-mode transmitter with tuned termination resistance
CA2618970C (en) * 2005-08-29 2015-03-31 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
US7491847B2 (en) * 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) * 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1991214B1 (en) * 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
CN101442997B (en) * 2006-04-03 2012-11-14 泰华制药工业有限公司 Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (en) * 2006-08-18 2008-02-27 Ratiopharm GmbH New salts of the active component rasagiline
AU2007334428B2 (en) * 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
NZ577623A (en) * 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
EP2194780A4 (en) * 2007-09-05 2010-10-27 Teva Pharma Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CN101909438A (en) * 2008-01-11 2010-12-08 泰华制药工业有限公司 Rasagiline formulations, their preparation and use
MX2010013766A (en) * 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagiline for parkinson's disease modification.
AU2009260728B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
WO2009154782A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
JP5168646B2 (en) * 2008-07-08 2013-03-21 株式会社リコー Image forming apparatus
DE102008064061A1 (en) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Solid composition with the active ingredient rasagiline
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
EP2485722A1 (en) * 2009-10-09 2012-08-15 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of progressive supranuclear palsy
US20110152381A1 (en) * 2009-12-22 2011-06-23 Anton Frenkel 3-keto-n-propargyl-1-aminoindan
JP2013537530A (en) * 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド Rasagiline citrate dispersion
JP2013533287A (en) * 2010-07-27 2013-08-22 テバ ファーマシューティカル インダストリーズ リミティド Use of rasagiline for the treatment of olfactory dysfunction
MX2013004598A (en) * 2010-10-26 2013-07-17 Teva Pharma Deuterium enriched rasagiline.

Also Published As

Publication number Publication date
EP1987816A1 (en) 2008-11-05
US20140072526A1 (en) 2014-03-13
WO2008131961A1 (en) 2008-11-06
CA2684977A1 (en) 2008-11-06
US20100137447A1 (en) 2010-06-03
EP2150238A1 (en) 2010-02-10

Similar Documents

Publication Publication Date Title
CA2684977C (en) A method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant
ES2389889T3 (en) Rasagiline delayed release formulation
JP6603306B2 (en) A new hydrate of dolutegravir sodium
JP2020090505A (en) Solid pharmaceutical compositions of androgen receptor antagonists
CN107595784B (en) Tacrolimus slow releasing medicinal compositions
CN107080742B (en) Solid dosage form pharmaceutical composition for oral administration
JP2009542647A (en) Memantine pharmaceutical composition
WO2020249001A1 (en) Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
EP2732810A1 (en) Spherical particles of clopidogrel bisulfate, pharmaceutical composition including same, and method for manufacturing same
MX2010008711A (en) Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability.
AU2010274589A1 (en) Oral pharmaceutical composition of rasagiline and process for preparing thereof
JP2023027312A (en) Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}pyrimidine-2,4-diamine
US10583087B2 (en) Pharmaceutical composition for oral administration
JP2020186190A (en) Istradefylline preparation
WO2008059298A2 (en) Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form
WO2013190151A1 (en) Pharmaceutical composition comprising fingolimod
JP7264711B2 (en) Method for producing pharmaceutical composition containing levetiracetam
WO2019097090A1 (en) Pharmaceutical tablet composition comprising bilastine and magnesium aluminometasilicate
US20110021631A1 (en) Method of preparing stabilized pharmaceutical compositions comprising active ingredients susceptible to conversion to alternate polymorph forms
WO2024153130A1 (en) Pharmaceutical composition comprising cyclic compound, preparation method therefor, and use thereof
EP3082772A1 (en) Pharmaceutical composition comprising amorphous ivabradine
US20160022661A1 (en) Dosage Form Comprising Crizotinib
WO2014192022A1 (en) Pharmaceutical compositions of rasagiline
CA3166050A1 (en) Stable immediate release tablet and capsule formulations of 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one
CN116370472A (en) Composition and microchip of donepezil, and preparation method and application thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130130

MKLA Lapsed

Effective date: 20160502